- Home
- PRPO vs SLXN Comparison
PRPO vs SLXN Comparison
Compare PRPO & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- SLXN
- Stock Information
- Founded
- PRPO N/A
- SLXN 2008
- Country
- PRPO United States
- SLXN Israel
- Employees
- PRPO N/A
- SLXN N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- SLXN
- Sector
- PRPO Industrials
- SLXN
- Exchange
- PRPO Nasdaq
- SLXN NYSE
- Market Cap
- PRPO 9.9M
- SLXN 7.6M
- IPO Year
- PRPO N/A
- SLXN N/A
- Fundamental
- Price
- PRPO $6.65
- SLXN $1.26
- Analyst Decision
- PRPO
- SLXN Strong Buy
- Analyst Count
- PRPO 0
- SLXN 1
- Target Price
- PRPO N/A
- SLXN $9.00
- AVG Volume (30 Days)
- PRPO 6.6K
- SLXN 32.0M
- Earning Date
- PRPO 03-28-2025
- SLXN 02-21-2025
- Dividend Yield
- PRPO N/A
- SLXN N/A
- EPS Growth
- PRPO N/A
- SLXN N/A
- EPS
- PRPO N/A
- SLXN N/A
- Revenue
- PRPO $17,411,000.00
- SLXN N/A
- Revenue This Year
- PRPO $75.18
- SLXN N/A
- Revenue Next Year
- PRPO N/A
- SLXN N/A
- P/E Ratio
- PRPO N/A
- SLXN N/A
- Revenue Growth
- PRPO 31.31
- SLXN N/A
- 52 Week Low
- PRPO $4.31
- SLXN $0.21
- 52 Week High
- PRPO $7.20
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- PRPO 63.80
- SLXN N/A
- Support Level
- PRPO $6.52
- SLXN N/A
- Resistance Level
- PRPO $6.90
- SLXN N/A
- Average True Range (ATR)
- PRPO 0.27
- SLXN 0.00
- MACD
- PRPO 0.03
- SLXN 0.00
- Stochastic Oscillator
- PRPO 89.90
- SLXN 0.00
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.